Arvinas Names Randy Teel as CEO, Targets LRRK2, BCL6 and KRAS Data
Arvinas appointed Randy Teel, PhD, as President, CEO and Director effective Feb. 12, succeeding John Houston, who will remain board consultant. Teel, Arvinas’ CBO since 2018, led its IPO and refocused strategy on its clinical pipeline as data from LRRK2, BCL6 and KRAS G12D degrader programs loom later this year.
1. Leadership Change at Arvinas
Arvinas appointed Randy Teel, PhD, as President, Chief Executive Officer and Director effective Feb. 12. Teel succeeds John Houston, PhD, who retires as CEO and Board Chair and will continue as a board consultant. Briggs Morrison, MD, has been elected Chair of the Board.
2. Strategic Focus and Upcoming Catalysts
Teel, who served as Chief Business Officer since 2018, led Arvinas’ 2018 IPO and steered corporate strategy and business development. Under his leadership, the company will advance its PROTAC pipeline, with pivotal data expected from LRRK2, BCL6 and KRAS G12D degrader programs later this year.